Hemab Therapeutics (COAG) News
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
39.29-0.57 (-1.43%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
COAG news summary
We found 8 recent headlines mentioning Hemab Therapeutics (COAG): 0 in the past week and 7 in the past 30 days, most often from GlobeNewswire, Nasdaq, Investing.com. For price context, COAG is down 1.43% at $39.29. The most recent story, "Hemab Therapeutics to Participate in Upcoming Investor Conferences", was published by GlobeNewswire on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Hemab Therapeutics headlines
- Hemab Therapeutics to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment…GlobeNewswire
- Hemab (COAG) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Why is Hemab Therapeutics stock sliding today?Investing.com
- Hemab Therapeutics Holdings GAAP EPS of -$0.58 misses by $0.06Seeking Alpha
- Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateDosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. aloneGlobeNewswire
- Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann ThrombastheniaHemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombastheniaGlobeNewswire
- Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and ExpositionFirst clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial…GlobeNewswire
- Rodman & Renshaw Initiates Coverage of Hemab Therapeutics Holdings with BuyFintel reports that on October 12, 2026, Rodman & Renshaw initiated coverage of Hemab Therapeutics Holdings (NASDAQGS:COAG) with a Buy recommendation. On the day of the coverage initiation, October…Nasdaq